@article {Klingler2020.08.18.20177303, author = {J{\'e}romine Klingler and Svenja Weiss and Vincenza Itri and Xiaomei Liu and Kasopefoluwa Y. Oguntuyo and Christian Stevens and Satoshi Ikegame and Chuan-Tien Hung and Gospel Enyindah-Asonye and Fatima Amanat and Ian Baine and Suzanne Arinsburg and Juan C. Bandres and Erna Milunka Kojic and Jonathan Stoever and Denise Jurczyszak and Maria Bermudez-Gonzalez and Viviana Simon and Sean Liu and Benhur Lee and Florian Krammer and Susan Zolla-Pazner and Catarina E. Hioe}, title = {Role of IgM and IgA Antibodies to the Neutralization of SARS-CoV-2}, elocation-id = {2020.08.18.20177303}, year = {2020}, doi = {10.1101/2020.08.18.20177303}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {SARS-CoV-2 has infected millions of people and is on a trajectory to kill more than one million globally. Virus entry depends on the receptor-binding domain (RBD) of the spike protein. Although previous studies demonstrated anti-spike and {\textendash}RBD antibodies as essential for protection and convalescent plasma as a promising therapeutic option, little is known about the immunoglobulin (Ig) isotypes capable of blocking virus entry. Here, we studied spike- and RBD-specific Ig isotypes in plasma/sera from two acutely infected and 29 convalescent individuals. Spike- and RBD-specific IgM, IgG1, and IgA1 antibodies were produced by all or nearly all subjects at varying levels and detected at 7{\textendash}8 days post-disease onset. IgG2, IgG3, IgG4, and IgA2 were also present but at much lower levels. All samples also displayed neutralizing activity. IgM, IgG, and IgA were capable of mediating neutralization, but neutralization titers correlated better with binding levels of IgM and IgA1 than IgG.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the Microbiology Laboratory Clinical Services at the Mount Sinai Health System and the Mount Sinai Health System Translational Science Hub, National Institutes of Health [grant U54TR001433]; the Personalized Virology Initiative supported by institutional funds and philanthropic donations (to V.S.); the Department of Medicine of the Icahn School of Medicine at Mount Sinai Department of Medicine (to S.Z-P., C.E.H.); the Department of Microbiology and the Ward-Coleman estate for endowing the Ward-Coleman Chairs at the Icahn School of Medicine at Mount Sinai (to B.L.), the National Institute of Allergy and Infectious Diseases Centers of Excellence for Influenza Research and Surveillance [contract HHSN272201400008C] (to F.K., V.S.); the Department of Veterans Affairs [Merit Review Grant I01BX003860] (to C.E.H.) and [Research Career Scientist Award 1IK6BX004607] (to C.E.H.); the National Institute of Allergy and Infectious Diseases [grant AI139290] to C.E.H., [grant AI136916] (to V.S.), [grants R01 AI123449, R21 AI1498033] to B.L. K.Y.O. and C.S. were supported by Viral-Host Pathogenesis Training Grant T32 AI07647; K.Y.O. was additionally supported by F31 AI154739. S.I. and C-T. H. were supported by postdoctoral fellowships from CHOT-SG (Fukuoka University, Japan) and the Ministry of Science and Technology (MOST, Taiwan), respectively.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRBs at Icahn School of Medicine at Mount Sinai and the James J. Peter VA Medical CenterAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw data that support the findings of this study are available from the corresponding author upon request.}, URL = {https://www.medrxiv.org/content/early/2020/08/21/2020.08.18.20177303}, eprint = {https://www.medrxiv.org/content/early/2020/08/21/2020.08.18.20177303.full.pdf}, journal = {medRxiv} }